Biologic facts
BrandActemra (Tocilizumab)
3 tocilizumab biosimilars from 3 makers are licensed, 1 of them interchangeable. The 12-year reference exclusivity date of 01/2022 is an estimate from first approval; the Purple Book does not list patents, which can protect a biologic longer.
Actemra was first approved by the FDA in 2010; the application holder is Genentech, Inc.
The latest NADAC for ACTEMRA ACTPEN 162 MG/0.9 ML is $1,279.06 per mL (as of 10/28/2026).
Holder Genentech, Inc.Approved 2010
01Exclusivity
When biosimilar competition can legally begin. The Purple Book lists reference exclusivity but not patents, which can protect a biologic longer.
- Patents
- Not listed in the Purple Book Purple Book
- Reference exclusivity
- 01/202212-year estimate from first approval Purple Book
02Competition
- Biosimilars
- 3 biosimilars from 3 makers Purple Book
- Interchangeable
- 1 Purple Book
Every makerEach licensed product and biosimilar maker.
PrescribersWho prescribes it, from Medicare data.
Spend and safetyMedicare Part B spend and safety reports.
Available in the full Actemra profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $1,279.06 per mLACTEMRA ACTPEN 162 MG/0.9 ML, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Genentech, Inc. Purple Book
- First approved
- 2010 Purple Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.